Sierra Oncology Inc - ESG Rating & Company Profile powered by AI
The webpage contains a zero-cost E,S&G analysis covering Sierra Oncology Inc. Scroll down to the bottom of the page for potential risks for Sierra Oncology Inc based on industry, location and size. This article includes a questions and answers table for Sierra Oncology Inc.
Sierra Oncology Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.0; made up of an environmental score of 2.0, social score of 2.7 and governance score of 6.9.
4.0
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 1412 | Vallon Pharmaceuticals Inc | 4.1 | High |
| 1412 | Vectura Group PLC | 4.1 | High |
| 1443 | Sierra Oncology Inc | 4.0 | High |
| 1443 | Adaptive Biotechnologies Corp | 4.0 | High |
| 1443 | Ascletis Pharma Inc | 4.0 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Sierra Oncology Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Sierra Oncology Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Sierra Oncology Inc report the average age of the workforce?
Sign up for free to unlockDoes Sierra Oncology Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Sierra Oncology Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Sierra Oncology Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Sierra Oncology Inc offer flexible work?
Sign up for free to unlockDoes Sierra Oncology Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Sierra Oncology Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Sierra Oncology Inc conduct supply chain audits?
Sign up for free to unlockDoes Sierra Oncology Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Sierra Oncology Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Sierra Oncology Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Sierra Oncology Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Sierra Oncology Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Sierra Oncology Inc disclose water use targets?
Sign up for free to unlockDoes Sierra Oncology Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Sierra Oncology Inc have a product recall in the last two years?
Sign up for free to unlockDoes Sierra Oncology Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Sierra Oncology Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Sierra Oncology Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Sierra Oncology Inc disclose parental leave metrics?
Sign up for free to unlockDoes Sierra Oncology Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Sierra Oncology Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Sierra Oncology Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Sierra Oncology Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Sierra Oncology Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Sierra Oncology Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Sierra Oncology Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Sierra Oncology Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Sierra Oncology Inc disclose its waste policy?
Sign up for free to unlockDoes Sierra Oncology Inc report according to TCFD requirements?
Sign up for free to unlockDoes Sierra Oncology Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Sierra Oncology Inc disclose energy use targets?
Sign up for free to unlockDoes Sierra Oncology Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Sierra Oncology Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Sierra Oncology Inc
These potential risks are based on the size, segment and geographies of the company.
Sierra Oncology, Inc. researches, develops, and commercializes therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has two completed Phase 3 trials for the treatment of myelofibrosis. The company also develops SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1; and SRA141, an orally bioavailable small molecule inhibitor of cell division cycle 7 kinase. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is based in San Mateo, California.